Arcus Biosciences ((RCUS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arcus Biosciences is conducting a clinical study titled ‘A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies.’ The study aims to assess the safety and tolerability of AB801, a new drug, in patients with advanced cancers, and to determine the recommended dose for further trials. This study is significant as it could lead to new treatment options for patients with limited alternatives.
The intervention being tested is AB801, administered orally in capsule or tablet form across various dose levels. In the dose expansion phase, AB801 is combined with Docetaxel, an existing chemotherapy drug, to treat non-small cell lung cancer (NSCLC).
The study design is interventional, non-randomized, and follows a sequential model with no masking, focusing on treatment. This approach allows researchers to adjust doses based on participant responses, ensuring safety and efficacy.
The study began on November 1, 2023, with primary completion expected by September 30, 2025. These dates are crucial as they guide the timeline for potential market entry and investor decisions.
This update could positively influence Arcus Biosciences’ stock performance by showcasing their commitment to innovation in cancer treatment. Investors may view this as a promising development, especially in comparison to competitors lacking similar advancements.
The study is ongoing, with further details available on the ClinicalTrials portal.